Quillan Huang, MD
Internal Medicine · Houston, TXNPI 1215270947
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,820 of the $8,178 with a category attached, or 71.2%. It is spread thinly across 22 manufacturers, the largest accounting for just 23.3%. Reporting peaked in 2023 at $3,818 and has fallen 77.6% since, to $855 in 2025. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 76 payments — averaging $107.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- AstraZeneca$1K
- Daiichi Sankyo Inc.$850
- Beigene USA, Inc.$675
- GSK$430
- plus $2K from 16 others
Across 1 payment — averaging $1035.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1K
What the payments were for
- Consulting fees$5,82071%
- Speaking & faculty fees$4005%
- Food & beverage$1,81022%
- Education$1472%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 2 | $1,907 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $1,667 |
| AstraZeneca(2 entities) | 16 | $1,017 |
| Daiichi Sankyo Inc. | 2 | $850 |
| Beigene USA, Inc. | 1 | $675 |
| GSK | 1 | $430 |
| Novocure GmbH | 1 | $200 |
| E.r. Squibb & Sons, L.L.C. | 5 | $182 |
| Astellas Pharma US Inc | 2 | $170 |
| Lilly USA, LLC | 7 | $158 |
| Tempus AI, Inc | 2 | $152 |
| Bayer | 3 | $146 |
| Bristol Myers Squibb | 12 | $144 |
| Incyte Corporation | 3 | $104 |
| Novartis | 4 | $91 |
| Pfizer | 4 | $69 |
| Amgen | 2 | $65 |
| Merck | 2 | $47 |
| Rigel Pharmaceuticals, Inc. | 2 | $35 |
| Eisai Inc. | 1 | $24 |
| Syndax Pharmaceuticals, Inc. | 1 | $24 |
| Array Biopharma Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,178 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Houston
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
- Krina PatelHouston$255K
- Nicholas ShortHouston$247K
- Naveen PemmarajuHouston$230K
- Mariana Chavez MacgregorHouston$188K
- Shumei KatoHouston$180K
- Sukhdeep BasraHouston$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.